An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer

NCT04089553 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

59

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Interventions

DRUG: AZD4635
DRUG: Oleclumab
DRUG: Durvalumab

Sponsor

AstraZeneca